PMN Stock Forecast & Price Target

ProMIS Neurosciences is positioned attractively because PMN310 has already shown differentiated interim PRECISE-AD data in 144 patients, including zero ARIA-E across all genotypes, placebo-like ARIA-H of 4.4%, and encouraging biomarker declines in pTau217 and MTBR-tau243, which strengthens confidence that its oligomer-selective approach can improve the safety profile that limits approved anti-amyloid therapies. The company also appears financially manageable in the near term, with a 2Q26 net loss of $11.7 million, R&D of $9.5 million, G&A of $2.7 million, and about $53.4 million in cash, which management says is sufficient to fund operations through 2027. Beyond Alzheimer’s, PMN267, PMN440, and PMN442 provide additional pipeline optionality in ALS, Parkinson’s-related alpha-synuclein, and other misfolded-protein diseases, supporting a multi-asset platform story with meaningful long-term upside.

ProMIS Neurosciences is a high-risk, precommercial biotechnology name whose valuation rests almost entirely on PMN310, despite the fact that its lead Alzheimer’s program remains unproven in humans and faces a difficult competitive landscape from approved anti-amyloid antibodies. While blinded data through Day 169 showed a 15% decline in plasma pTau217 and a 13.3% decline in CSF MTBR-tau243, the company still has to prove that these biomarker shifts translate into meaningful functional efficacy, safety without incremental ARIA, and durable differentiation. With a DCF enterprise value of $167M based on only a 20% probability of regulatory approval and a need to fund large, costly later-stage trials, the stock looks vulnerable to dilution and clinical disappointment.